Diabetic Macular Edema

Bandello, Francesco; Parodi, Maurizio Battaglia; Lanzetta, Paolo; Loewenstein, Anat; Massin, Pascale; Menchini, Francesca; Veritti, Daniele

doi:10.1159/000320075

Cited by 63 publications

(45 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Dennoch ist die fokale Laser photokoagulation, die in letzter Zeit ver mehrt durch intravitreale AntiVEGF Behandlung ergänzt wird, bei bestimm ten Formen des DMÖ immer noch Gold standard [1,7,21,28]. Jüngst veröffentli che Studienergebnisse scheinen aber an zudeuten, dass insbesondere eine Kom binationsbehandlung aus AntiVEGF mit modifizierten Laserprotokollen von Vor teil sein kann [24].…”

Section: Diskussionunclassified

“…Nach 20 Jahren Erkrankungs dauer leiden fast 100% der Patienten mit Typ1Diabetes und mehr als 60% der Pa tienten mit Typ2Diabetes an DR [8,16]. Die häufigste Ursache für den Verlust an zentraler Sehschärfe bei Patienten mit DR ist das diabetische Makulaödem (DMÖ; [1,7,16,23]). Neben neuen, vielverspre chenden medikamentösen Therapiean sätzen wie der intravitrealen Applika tion von Antikörper(fragmenten) gegen den Wachstumsfaktor "vascular endo thelial growth factor" (VEGF; [21,28]) stellt die retinale Laserphotokoagulation auch heute noch eine wichtige Therapie säule sowohl bei der proliferativen diabe tischen Retinopathie (PDR) als auch beim DMÖ dar [1,7].…”

unclassified

See 1 more Smart Citation

Navigierte fokale retinale Lasertherapie mit dem NAVILAS®-System bei diabetischem Makulaödem

et al. 2012

View full text Add to dashboard Cite

show abstract

Section: Diskussionunclassified

unclassified

Navigierte fokale retinale Lasertherapie mit dem NAVILAS®-System bei diabetischem Makulaödem

et al. 2012

View full text Add to dashboard Cite

show abstract

“…In particular, diabetic macular edema (DME) is the main cause of visual loss in diabetic patients [2]. The classification of DME is essential in defining the stage and therefore the severity of the disease, and is crucial in clinical decision-making.…”

Section: Introductionmentioning

confidence: 99%

A Pathogenetic Classification of Diabetic Macular Edema

et al. 2018

Self Cite

View full text Add to dashboard Cite

Purpose: The aim of this study was to define a new pathogenetic classification of diabetic macular edema (DME) and to present the results of its application in common clinical practice. Methods: One hundred and seventy-seven consecutive patients with center-involving DME, central retinal thickness (CRT) ≥250 µm, were prospectively enrolled. A complete ophthalmological examination included best-corrected visual acuity (BCVA) assessment, fundus photography, and spectral-domain optical coherence tomography (OCT). The DME classification was broken down into 4 categories, combining the presence of retinal thickening with the presence/absence of visible vascular dilations and OCT-detectable macular traction. The OCT parameters included were as follows: CRT, subretinal fluid, intraretinal cysts, and hyper- reflective foci (HF). Results: Four subtypes of DME were identified: vasogenic (131 eyes, DME with vascular dilation), nonvasogenic (46 eyes, DME without vascular dilation), tractional (11 eyes), and mixed DME (13 eyes). Vasogenic DME was the pattern mainly represented in each subclass of CRT (< 300, 300–400, and > 400 µm), with tractional DME observed especially with CRT > 400 µm. Internal and external cysts and a greater presence of hard exudates were predominantly found in vasogenic DME, whereas HF was equally distributed in the 4 DME subgroups. Conclusion: The study offers a new pathogenetic classification able to detect significant differences among DME subtypes. A tailored therapeutic approach could take into consideration specific changes associated with the different DME subtypes.

show abstract

“…Encouraging results emerged also from studies evaluating the use of a combination therapy, or the association of intravitreal drugs and laser treatment. However, DME-specific characteristics appear paramount in the choice of the best therapeutic approach [5]. …”

Section: Introductionmentioning

confidence: 99%

Pharmacological Approach to Diabetic Macular Edema

et al. 2013

View full text Add to dashboard Cite

Diabetic macular edema (DME) is a highly prevalent cause of vision loss and has a remarkable impact on public health, and on the quality of life of diabetic patients. Even though laser photocoagulation has been the standard of care for decades, a substantial group of patients are unresponsive and fail to improve after laser treatment. Recently, new pharmacological approaches based on the use of intravitreal drugs, such as corticosteroids and anti-vascular endothelial growth factor, have revolutionized the treatment of DME. The use of intravitreal drugs is supported by the improvement in visual acuity reported by several clinical trials and can limit the potentially destructive effects of the laser treatment. Encouraging results also emerged from studies evaluating the use of a combination therapy, or the association of intravitreal drugs and laser treatment. This review aims at providing a brief synopsis of the main investigations regarding the current pharmacological approach to DME.

show abstract

Diabetic Macular Edema

Cited by 63 publications

References 0 publications

Navigierte fokale retinale Lasertherapie mit dem NAVILAS®-System bei diabetischem Makulaödem

Navigierte fokale retinale Lasertherapie mit dem NAVILAS®-System bei diabetischem Makulaödem

A Pathogenetic Classification of Diabetic Macular Edema

Pharmacological Approach to Diabetic Macular Edema

Contact Info

Product

Resources

About